Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, the trans-radial (TR) route has become the preferred way.3 The TR route offers better procedure comfort, shorter hospitalization […]

Ajay Kirtane, TCT 2022: The benefits of ultrasound renal denervation for patients with uncontrolled hypertension, the RADIANCE II trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 10th 2022

The RADIANCE II trial aimed to build on existing data to demonstrate that ultrasound renal denervation can lower blood pressure in patients with uncontrolled hypertension. In this touchCARDIO interview, we speak with Dr Ajay Kirtane (Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY, USA) to discuss the outcomes of the RADIANCE II trial and the clinical implications of these findings.

The abstract entitled ‘Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.

Questions:

  1. How did the RADIANCE II trial build on existing knowledge, and what type of patients were included in the study? (0:17)
  2. What were the key findings from the RADIANCE II trial? (1:19)
  3. Did you see any notable safety signals or common adverse events in using ultrasound renal denervation for patients with hypertension? (2:20)
  4. How do you think these trial findings can be incorporated into future routine practice, and contribute to more efficacious management of uncontrolled hypertension? (2:59)

Disclosures: Ajay Kirtane is a consultant for IMDS, has received expenses from Abbott Vascular, Boston Scientific, Chiesi, CSI, Medtronic, OpSens, Philips, ReCor Medical, Regeneron, Siemens and Zoll. Ajay Kirtane reports Institutional funding to Columbia University and/or Cardiovascular Research Foundation from Abbott Vascular, Amgen, Biotronik, Bolt Medical, Boston Scientific, Canon, Chiesi, CSI,  Magenta Medical, Medtronic, Merck, Neurotronic, Philips, ReCor Medical, Shockwave Medical and SoniVie. In addition to research grants, institutional funding includes fees paid to Columbia University and/or Cardiovascular Research Foundation for consulting and/or speaking engagements in which he controlled the content.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of TCT 2022

Access more content on Hypertension here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup